Whaley Kevin J, Hiatt Andrew, Zeitlin Larry
Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
Hum Vaccin. 2011 Mar;7(3):349-56. doi: 10.4161/hv.7.3.14266. Epub 2011 Mar 1.
Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.
由于成本高昂、生产能力有限以及生产周期长，基于抗体的产品无法广泛用于应对多种全球健康挑战。由于瞬时表达和糖基化途径改变方面的革命性进展，基于烟草的抗体产品制造现在可能开始应对这些挑战。本综述提供了新兴的基于抗体的产品（粘膜和全身用）的例子，当利用基于烟草的制造的特性（大规模、通用、快速、低成本）时，这些产品可能具有竞争力并在商业上可行。
